Kymera Therapeutic/$KYMR
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kymera Therapeutic
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of, differentiated medicines that address health problems and that meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.
Ticker
$KYMR
Sector
Primary listing
Employees
218
Headquarters
Website
KYMR Metrics
BasicAdvanced
$3B
-
-$3.48
2.18
-
Price and volume
Market cap
$3B
Beta
2.18
52-week high
$51.84
52-week low
$19.45
Average daily volume
648K
Financial strength
Current ratio
8.32
Quick ratio
8.059
Long term debt to equity
7.416
Total debt to equity
8.823
Interest coverage (TTM)
-996.36%
Profitability
EBITDA (TTM)
-305.056
Gross margin (TTM)
-550.56%
Net profit margin (TTM)
-616.03%
Operating margin (TTM)
-697.51%
Revenue per employee (TTM)
$210,000
Management effectiveness
Return on assets (TTM)
-19.92%
Return on equity (TTM)
-33.26%
Valuation
Price to revenue (TTM)
74.789
Price to book
3.06
Price to tangible book (TTM)
3.06
Price to free cash flow (TTM)
-13.221
Free cash flow yield (TTM)
-7.56%
Free cash flow per share (TTM)
-3.192
Growth
Revenue change (TTM)
-49.51%
Earnings per share change (TTM)
43.55%
3-year revenue growth (CAGR)
-7.64%
3-year earnings per share growth (CAGR)
8.62%
What the Analysts think about KYMR
Analyst ratings (Buy, Hold, Sell) for Kymera Therapeutic stock.
Bulls say / Bears say
Brokerages including BofA and Morgan Stanley reaffirmed Buy ratings for Kymera after KT-621 substantially lowered STAT6 levels in blood and skin in its Phase 1 trial, strengthening market confidence in Kymera’s oral degrader platform (Reuters).
Kymera entered a strategic partnership with Gilead to develop CDK2 molecular glue degraders, with up to $750 million in potential payments, validating its targeted protein degradation technology and expanding its pipeline (Reuters).
As of July 31, 2025, Kymera had about $1 billion in cash—boosted by a $250 million equity raise and Gilead’s upfront payment—extending its financial runway into the second half of 2028 to support several clinical programs (GlobeNewswire).
Sanofi’s decision to deprioritize its lead IRAK4 degrader KT-474 in favor of the preclinical candidate KT-485 delays Kymera’s IRAK4 franchise and increases execution risk (Fierce Biotech).
Kymera’s decision to halt development of its TYK2 degrader KT-295 reduces pipeline diversification and raises dependence on early-stage assets like KT-621 and KT-579 (GlobeNewswire).
In Q1 2025, Kymera’s R&D expenses reached $80.3 million, while collaboration revenue was $22.1 million, highlighting significant cash burn and raising the risk of future dilution if extra funding is needed (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
KYMR Financial Performance
Revenues and expenses
KYMR Earnings Performance
Company profitability
KYMR News
AllArticlesVideos
Gilead signs up to $750 million cancer drug deal with Kymera Therapeutics
Reuters2 months ago
Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
Business Wire2 months ago
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
MarketBeat3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kymera Therapeutic stock?
Kymera Therapeutic (KYMR) has a market cap of $3B as of September 05, 2025.
What is the P/E ratio for Kymera Therapeutic stock?
The price to earnings (P/E) ratio for Kymera Therapeutic (KYMR) stock is 0 as of September 05, 2025.
Does Kymera Therapeutic stock pay dividends?
No, Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders as of September 05, 2025.
When is the next Kymera Therapeutic dividend payment date?
Kymera Therapeutic (KYMR) stock does not pay dividends to its shareholders.
What is the beta indicator for Kymera Therapeutic?
Kymera Therapeutic (KYMR) has a beta rating of 2.18. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.